Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670428 | 0.86 | YAP1 (0.53) | MAPK14MCHR1 | |
| SCHEMBL6043950 | 0.84 | MAPK14 (0.48) | MAPK14MCHR1KCNH2 | |
| SCHEMBL6042068 | 0.84 | MAPK14 (0.48) | MAPK14MCHR1KCNH2 | |
| SCHEMBL16669951 | 0.77 | MAPK14 (0.52) | MAPK14ALDH1A1 | |
| SCHEMBL5862299 | 0.77 | MAPK14 (0.52) | MAPK14ALDH1A1 | |
| SCHEMBL6041786 | 0.76 | MCHR1 (0.41) | MAPK14MCHR1KCNH2 | |
| SCHEMBL6043024 | 0.76 | MCHR1 (0.41) | MAPK14MCHR1KCNH2 | |
| SCHEMBL5429002 | 0.75 | KDM5A (0.47) | ALDH1A1 | |
| SCHEMBL30031731 | 0.75 | SMN1; SMN2 (0.56) | HRH3 | |
| SCHEMBL6470884 | 0.75 | MAPK14 (0.54) | MAPK14MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063139-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-21 | — | — | EP | disclosed |
| EP-3063139-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | MAPK14 333/4885MCHR1 96/4885KCNH2 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.